Repositioning Candidate Details
| Candidate ID: | R0514 |
| Source ID: | DB01407 |
| Source Type: | approved; investigational; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Clenbuterol |
| Synonyms: | (±)-clenbuterol; 1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol; 4-amino-3,5-dichloro-α-(((1,1-dimethylethyl)amino)methyl)benzenemethanol; 4-amino-α-((tert-butylamino)methyl)-3,5-dichlorobenzyl alcohol |
| Molecular Formula: | C12H18Cl2N2O |
| SMILES: | CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 |
| Structure: |
|
| DrugBank Description: | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. |
| CAS Number: | 37148-27-9 |
| Molecular Weight: | 277.19 |
| DrugBank Indication: | Used as a bronchodilator in the treatment of asthma patients. |
| DrugBank Pharmacology: | Clenbuterol is a substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. Although approved for use in some countries, as of fall, 2006, clenbuterol is not an ingredient of any therapeutic drug approved by the U.S. Food and Drug Administration. |
| DrugBank MoA: | Clenbuterol is a Beta(2) agonist similar in some structural respects to salbutamol. Agonism of the beta(2) receptor stimulates adenylyl cyclase activity which ultimately leads to downstream effects of smooth muscle relaxation in the bronchioles. |
| Targets: | Beta-2 adrenergic receptor agonist; Beta-1 adrenergic receptor agonist; Beta-3 adrenergic receptor agonist; Beta-nerve growth factor stimulator; Tumor necrosis factor other/unknown |
| Inclusion Criteria: | Target associated |
